Amplatzer™ Amulet™ LAAO

AMPLATZER™ AMULET™
LAA OCCLUDER
STRUCTURAL INTERVENTIONS

Designed to treat patients with non-valvular atrial fibrillation (AF), who are at risk of ischemic stroke, the Amplatzer™ Amulet™ LAA Occluder offers complete closure of the left atrial appendage (LAA) and immediately eliminates the need for oral anticoagulants (OACs).¹

SWITCH TO THE REFERRAL VIEW For more information specific to neurology regarding LAA Occlusion

KEY FEATURES

Innovative dual seal technology

The Amulet™ Occluder's innovative dual seal technology leverages a proven Amplatzer™ design that has been trusted for over 20 years.¹

1

The lobe is designed to conform to different LAA anatomies including the hard to treat chicken wing and double lobe due to its proximal placement

2

The disc completely seals the LAA orifice creating a smooth surface to minimize the risk of a device-related thrombus (DRT) and offering a double sealing mechanism to decrease the risk of peri-device leaks (PDL)

3

Stabilizing wires secure the device in position to prevent embolization

FIND OUT MORE:

GUIDELINES & RECOMMENDATIONS

More sizes for more anatomies

The Amulet™ Occluder offers a full range of sizes to ensure a precise fit across all LAA anatomies.

Physician education

Hear from physicians how the Amplatzer™ Amulet™ Occluder can benefit physicians and help patients live longer, fuller lives.

WATCH LAAO SUMMIT 2024

NEW VERSION AVAILABLE
GET THE AMPLATZER™ PORTFOLIO APP

The Amplatzer™ Portfolio App helps physicians determine which Amplatzer Structural Interventions device to use by suggesting applicable devices based on respective Instructions for Use.

Connext
TV

CONNECT TO THE LATEST
IN STRUCTURAL HEART
THERAPY

Find out more

TV

Left Atrial Appendage Occlusion (LAAO)

Atrial Septal Defects (ASD)

Anatomical overview of the heart

Anatomical overview of the heart with focus on ASD, PFO and LAAO

LAAO Summit - Imaging debate: Mini TEE

Imaging debate: defending Mini TEE

N. Wunderlich

LAAO Summit - New data & future trials

New data, ongoing & future trials

K. Kaczmarek

LAAO Summit - Debate: Factor XI inhibitors

Debate: Factor XI inhibitors are close

J. Camm

LAAO Summit - Debate: Factor XI inhibitors

Debate: Factor XI inhibitors are far away

H.C. Diener

LAAO Summit - Imaging debate: TEE

Imaging debate: defending TEE

L. Boldt

LAAO Summit - Imaging debate: ICE

Imaging debate: defending ICE

J. Saw

LAAO Summit - Pre-procedural imaging

Pre-procedural imaging modalities

O. de Backer

References

Amplatzer™ Amulet™ LAA Occluder Instructions for Use.
Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer™ Amulet™ Left Atrial Appendage Occluder versus Watchman™ device for stroke prophylaxis (Amulet IDE): A randomized, controlled trial. Circulation. 2021; 144(19) :1543–1552. doi.org/10.1161/CIRCULATIONAHA.121.057063.
Suradi HS, Hijazi ZM. Left atrial appendage closure: outcomes and challenges. Neth Heart J. 2017;25:143–151. doi.org/10.1007/s12471-016-0929-0.
Kakkar AK, Mueller I, Bassand J-P, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. PLoS ONE. 2013; 8(5):e63479. doi.org/10.1371/journal.pone.0063479.
Baman JR, Mansour M, Heist EK, et al. Percutaneous left atrial appendage occlusion in the prevention of stroke in atrial fibrillation: a systematic review. Heart Failure Rev. 2018;23:191–208. doi.org/10.1007/s10741-018-9681-4.
European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery; Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429. doi.org/10.1093/eurheartj/ehq278. Erratum in: Eur Heart J. 2011;32(9):1172. PMID: 20802247.